ta-Scan can facilitate:

What our clients say about ta-Scan

Our comparative evaluation has clearly shown that the content of ta-Scan and the analytical tools incorporated in the platform, as well as the 99% accuracy of the included trials, were a trusted basis for our ongoing clinical planning functions.

In order to improve the overall trial feasibility process, Novartis Pharma AG realized that existing internal platforms, a reliance on local affiliate team members and the ad hoc utility of external vendors were neither cost effective nor timely. The decision to build the Clinical Trial Intelligence (CTI) unit combined with a comprehensive assessment of the external tools was undertaken. We evaluated MDCPartners’ ta-Scan tool and one other major supplier of a Trial and Site intelligence platform against a range of predetermined tests.

We performed a detailed review of the trials that were included in both tools in the indications of Rheumatoid Arthritis, Psoriasis, COPD and Renal Insufficiency, and assessed the data rendered for best in class for trial analytics and clinical studies planning.

We have more than three years of experience with ta-Scan and found our decision to purchase validated and have gained significant productivity savings. Our feasibility and allocation performance has continually improved and this has translated to an overall trial performance that outperforms our key competitors.

Novartis Pharma AG

The ta-Scan tools we use most frequently are the Site and KOL identification and drill-down profiles. The recent addition of the Trial Feasibility Wizard has proven to be a very valuable asset and time saver. ta-Scan also provides numerous updates and modifications at no cost to the customer. This is a tremendous benefit.

GlaxoSmithKline has evaluated ta-Scan in terms of content and usability and compared it to other intelligence tools on the market. Our preference goes out to ta-Scan because of

  • the depth of information on trials: more accurate and more data points for analysis (enrollment, timings, etc.) for our study planning and feasibility
  • the linking of trial information to sites, investigators, drugs in development, publications, etc. Other vendors split these services up as separate products, making it more time-consuming to use and more expensive.
  • the time saved for a feasibility project manager is as high as 2,5 weeks research work per study project. The ta-Scan tools we use most frequently are the Site and KOL identification and drill-down profiles. The recent addition of the Trial Feasibility Wizard has proven to be a very valuable asset and time saver. ta-Scan also provides numerous updates and modifications at no cost to the customer. This is a tremendous benefit.
GlaxoSmithKline

ta-Scan Trial Feasibility Wizard

This wizard will help you chart enrollment success and optimize your country allocation. The TFW benchmarks essential recruitment variables, enrollment slope, competing trials and site capacity in one simple report output.

See the wizard in action